Clinical trial NCT04672434: Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Official title: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Cancer
Solid Tumor
Keywords: Locally advanced/unresectable
Metastatic solid tumor
Anti-PD-1
PD-1
PD1
CD73
Squamous cell carcinoma of the head and neck (SCCHN)
Non-small-cell lung carcinoma-adenocarcinoma histology subtype (NSCLC-Adeno)
Pancreatic ductal adenocarcinoma (PDAC)
Cholangiocarcinoma (CCA)
Colorectal carcinoma (CRC)
Gastric carcinoma (GC)
Esophageal carcinoma (EsoCA)
Mesothelioma (Meso)
Sym021
Sym024
Head and neck squamous cell carcinoma (HNSCC)
Cervical carcinoma (CC)
Lead sponsor: Symphogen A/S
Sponsor class: INDUSTRY
First posted: 2020-12-17
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.

Detailed description: Part 1 of this study will assess the safety and tolerability to establish the maximum tolerated dose (MTD) (or the maximum administered dose \[MAD\]) and/or the selected dose(s) of Sym024 in patients with solid tumor malignancies.

Part 2 of this study will assess the safety and tolerability to establish the MTD (or the MAD) and/or the selected dose(s) of Sym024 when administered in combination with Sym021 in patients with solid tumor malignancies.

Part 2a of this study will assess the safety and tolerability of Sym024 when first administered as a single agent during Cycle 1 (safety lead-in) followed by administration in combination with Sym021 during Cycle 2 and subsequent cycles.

Part 3 of this study will assess the safety of Sym024 when administered alone or in combination with Sym021 in expanded cohorts of patients with solid tumor malignancies.

April 2024: The above was the study design at trial start. Per protocol, implementation of a part 3 would require an amendment. However, this was never done as it was decided not to include a part 3.

Eligibility criteria: Inclusion Criteria:

* Male or female patients, ≥18 years.
* Documented (histologically or cytologically proven), locally advanced or metastatic solid tumor malignancy (must be one of the following):

  1. Squamous cell carcinoma of the head and neck
  2. Non-small-cell lung carcinoma-adenocarcinoma histology subtype
  3. Pancreatic ductal adenocarcinoma
  4. Cholangiocarcinoma
  5. Colorectal carcinoma (microsatellite stable \[MSS\] and microsatellite instability-high \[MSI-H\] phenotypes)
  6. Gastric carcinoma (includes gastroesophageal carcinoma)
  7. Esophageal carcinoma (includes squamous cell and adenocarcinoma)
  8. Mesothelioma (pleural and peritoneal)
  9. Cervical carcinoma (CC) (includes adeno, squamous and mixed adeno-squamous carcinoma histology subtypes)
* Malignancy that is not currently amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.
* Measurable disease according to RECIST v1.1.
* Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.
* Agreeing to mandatory tumor tissue biopsies (2 total).
* ECOG PS of 0 or 1.
* Adequate organ function as indicated by the following laboratory values.
* Adequate contraception required as appropriate.

Exclusion Criteria:

* Central nervous system (CNS) malignancies.
* Clinically significant cardiovascular disease or condition.
* Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study drug(s).
* Active uncontrolled bleeding or a known bleeding diathesis.
* Significant ocular disease or condition.
* Significant pulmonary disease or condition.
* Current or recent (within 6 months) significant gastrointestinal disease or condition.
* Active, known or suspected autoimmune disease.
* History of organ transplantation (i.e., stem cell or solid organ transplant).
* Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
* Any other serious/active/uncontrolled infection.
* History of significant toxicities associated with previous administration of immune checkpoint inhibitors.
* Known or suspected hypersensitivity to any of the excipients of formulated study drug.
* Unresolved \>Grade 1 toxicity associated with any prior antineoplastic therapy.
* Inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to the first dose of study drug(s).
* Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy).

Therapeutic Exclusions

* Prior therapy with Sym024 or other inhibitors of CD73, CD39 or adenosine receptors ADORA2A, ADORA2B.
* Part II and Part III, prior anti-PD-(L)1 therapy, except for indications where it is approved.
* Any antineoplastic agent for the primary malignancy (standard or investigational) within 4 weeks or 5 elimination half-lives.
* Any other investigational treatments within 2 weeks prior to the first dose of study drug(s).
* Radiotherapy, with exceptions.
* Live vaccines against infectious diseases 4 weeks prior to the first dose of study drug(s).
* Immunosuppressive or systemic glucocorticoids therapy (\>10 mg daily prednisone or equivalent) within 2 weeks prior to the first dose of study drug(s), with exceptions.
* Prophylactic use of hematopoietic growth factors within 1 week prior to the first dose of study drug(s).

Primary outcomes:
measure: Part I: To evaluate the incidence, severity and relationship of (S)AEs to establish the MTD/MAD of Sym024 monotherapy.
timeFrame: 28 days
measure: Part II: To evaluate the incidence, severity and relationship of (S)AEs to establish MTD/MAD of Sym024 in combination with Sym021.
timeFrame: 28 days
measure: Part III: To evaluate the incidence, severity and relationship of (S)AEs to further assess safety of Sym024 when administered alone or in combination with Sym021.
timeFrame: 12 months
Secondary outcomes:
measure: Evaluation of the immunogenicity of Sym024 as a single agent and in combination with Sym024
timeFrame: 24 months
measure: Evaluation of objective response (OR) or stable disease (SD)
timeFrame: 24 months
measure: Time to progression (TTP) of disease
timeFrame: 24 months
measure: Area under the concentration-time curve in a dosing interval (AUC)
timeFrame: 24 months
measure: Maximum concentration (Cmax)
timeFrame: 24 months
measure: Time to reach maximum concentration (Tmax)
timeFrame: 24 months
measure: Trough concentration (Ctrough)
timeFrame: 24 months
measure: Terminal elimination half-life (T½)
timeFrame: 24 months
measure: Clearance (CL)
timeFrame: 24 months
Other outcomes:
Locations:
city: Grand Rapids
country: United States
facility: START Midwest
state: Michigan
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: San Antonio
country: United States
facility: NEXT Oncology
state: Texas
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: START Midwest, USA
name: N. Lakhani, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: